Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 829-840

  Travelli, Cristina ^a   Drago, Valentina ^a   Maldi, Elena ^a   Kaludercic, Nina ^b   Galli, Ubaldina ^a   Boldorini, Renzo ^a   Di Lisa, Fabio ^b   Tron, Gian Cesare ^a   Canonico, Pier Luigi ^a   Genazzani, Armando A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; ADENOSINE TRIPHOSPHATE; AUTOPHAGY RELATED PROTEIN 7; CELL PROTEIN; CHLOROQUINE; CISPLATIN; DAPORINAD; ETOPOSIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION;

ACRYLAMIDES; ADENOSINE; ADENOSINE TRIPHOSPHATE; ANNEXIN A5; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHLOROQUINE; CISPLATIN; COMET ASSAY; DNA DAMAGE; DOWN-REGULATION; DRUG SYNERGISM; ETOPOSIDE; HUMANS; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; NEUROBLASTOMA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; UBIQUITIN-ACTIVATING ENZYMES;

EID: 80052176231     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184630     Document Type: Article

References (40)

1. Berger F, Ramírez-Hernández MH, and Ziegler M (2004) The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci 29:111-118.
2. Bi TQ and Che XM (2010) Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 10:119-125.
3. Billington RA, Bruzzone S, De Flora A, Genazzani AA, Koch-Nolte F, Ziegler M, and Zocchi E (2006) Emerging functions of extracellular pyridine nucleotides. Mol Med 12:324-327. (Pubitemid 46489827)
4. Billington RA, Genazzani AA, Travelli C, and Condorelli F (2008a) NAD depletion by FK866 induces autophagy. Autophagy 4:385-387. (Pubitemid 351458108)
5. Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA, Canonico PL, Condorelli F, and Genazzani AA (2008b) Characterization of NAD uptake in mammalian cells. J Biol Chem 283:6367-6374.
6. Bogan KL and Brenner C (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28:115-130.
7. Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, et al. (2009) A catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 4:e7897.
8. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, and De Smedt T (2008) Pharmacological inhibition of nicotinammide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3:e2267.
9. Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, Rocco I, Cirmena G, Casciaro S, Olcese F, et al. 2009 APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 113:6035-6037; author reply 6037-6038.
10. Colombano G, Travelli C, Galli U, Caldarelli A, Chini MG, Canonico PL, Sorba G, Bifulco G, Tron GC, and Genazzani AA (2010) A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J Med Chem 53: 616-623.
11. D'Mello SR, Galli C, Ciotti T, and Calissano P (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci USA 90:10989-10993. (Pubitemid 23354354)
12. Drevs J, Löser R, Rattel B, and Esser N (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23:4853-4858. (Pubitemid 38173905)
13. Fresu L, Dehpour A, Genazzani AA, Carafoli E, and Guerini D (1999) Plasma membrane calcium ATPase isoforms in astrocytes. Glia 28:150-155. (Pubitemid 29530613)
14. Fuchs D, Christofferson R, Stridsberg M, Lindhagen E, and Azarbayjani F (2009) Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. J Transl Med 12:7-16.
15. Gallí M, Van Gool F, Rongvaux A, Andris F, and Leo O (2010) The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 70:8-11.
16. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, and Sobol RW (2011) Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 71:2308-2317.
17. Haigis MC and Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5:253-295.
18. Hasmann M and Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63:7436-7442. (Pubitemid 37413486)
19. Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, and du Bois A (2010) Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther 10:1125-1136.
20. Hsu CP, Hariharan N, Alcendor RR, Oka S, and Sadoshima J (2009) Nicotinamide phosphoribosyltransferase regulates cell survival through autophagy in cardiomyocytes. Autophagy 5:1229-1231.
21. Imai S (2009) Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 15:20-28.
22. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, Jang HO, Yun I, Yoon KH, Kim YJ, et al. (2007) Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357:150-156. (Pubitemid 46574511)
23. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4:151-175.
24. Koch-Nolte F, Haag F, Guse AH, Lund F, and Ziegler M (2009) Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 2:mr1.
25. Kondo Y, Kanzawa T, Sawaya R, and Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734. (Pubitemid 41486365)
26. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, and Dang CV (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107:2037-2042.
27. Magni G, Orsomando G, Raffelli N, and Ruggieri S (2008) Enzymology of mammalian NAD metabolism in health and disease. Front Biosci 13:6135-6154.
28. Maris JM, Hogarty MD, Bagatell R, and Cohn SL (2007) Neuroblastoma. Lancet 369:2106-2120. (Pubitemid 46935947)
29. Mizushima N and Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3:542-545. (Pubitemid 350060049)
30. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, and Koutcher JA (2005) Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11:3503-3513.
31. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjørnelund J, Dawson KM, Dupuis M, and Duchosal MA (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113:3276-3286.
32. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, and Shimizu S (2009) Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 461:654-658.
33. Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M, and Nielsen SJ (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367:799-804.
34. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F, and Chiarugi A (2010) Inhibition of nicotinamide phosphoribosyl transferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 285:34106-34114.
35. Pivonková H, Sebest P, Pecinka P, Tichá O, Nemcová K, Brázdová M, Jagelská EB, Brázda V, and Fojta M (2010) Selective binding of tumor suppressor p53 protein to topologically constrained DNA: modulation by intercalative drugs. Biochem Biophys Res Commun 393:894-899.
36. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, and Hasmann M (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 11:313-321. (Pubitemid 44390171)
37. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, and Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301.
38. Thiele CJ (1998) Neuroblastoma cell lines. J Hum Cell Culture 1:21-53.
39. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, et al. (2007) Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130:1095-1107. (Pubitemid 47410271)
40. Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, Caffa I, Bedognetti D, Motta G, Ghio R, et al. (2010) Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 38:979-988.